CANBRIDGE-B (1228.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. James Qun Xue M.B.A., Ph.D. | Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board | 5.93M | -- | 1970 |
| Ms. Qian Ma | General Counsel, Board Secretary & Joint Company Secretary | -- | -- | -- |
| Ms. Chris Chen | Vice President of Human Resources | -- | -- | -- |
| Dr. Gerald F. Cox M.D., Ph.D. | Chief Development Strategist & Interim Chief Medical Officer | -- | -- | 1959 |
| Ms. Rebecca Zhang | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Dr. Jeff Kou Ph.D. | Director and Head of Program Management & Clinical Operations | -- | -- | -- |
| Dr. Jason West | Head of Global Gene Therapy Research | -- | -- | -- |
| Mr. Joe Shen | Senior Vice President | -- | -- | -- |
| Mr. Will Wang | Senior Director & Head of Production | -- | -- | -- |
| Ms. Suya Gao | Acting Head of Commercial Operations of Mainland China | -- | -- | -- |
CANBRIDGE-B
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 67
Description
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN106, an anti-C5 mAb that has completed Phase I b clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; CAN202, a gene therapy program utilizing AAV sL65 capsid for pompe disease; and CAN 203, a gene therapy program that utilizes AAV SMN1 for the treatment of spinal muscular atrophy. It has a license agreement with Mirum for the development, commercialization, and manufacturing, under certain conditions, of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available